Evaluation of the efficacy and safety of methotrexate in progressive sarcoidosis: a retrospective observational study
https://doi.org/10.18093/0869-0189-2020-30-2-213-218
Abstract
Sarcoidosis is epithelioid cell granulomatosis of unknown etiology. All the schemes of its treatment are of a recommendatory nature. Methotrexate (MTT) is considered a second-line drug in the treatment of sarcoidosis.
Methods. A retrospective observational study of patients with progressive sarcoidosis (n = 104), treated with MTT once a week, was carried out. Clinical, laboratory, functional and radiation parameters were evaluated with an interval of 3 months ≤ 1 year.
Results. The use of MTT was accompanied by an improvement in the radiation picture (64.1% by the end of the year), an improvement not only in spirometry parameters, starting from the 3rd month (54.7%), but also in the general condition of the patients (63.8% – at the 6th month). Adverse reactions with drug withdrawal were most often observed (15.4%) during the first 3 months, and subsequently their frequency decreased.
Conclusion. According to the results of the study, it was shown that methotrexate can be recommended for further use in progressive sarcoidosis, as well as in patients, who have previously received systemic glucocorticosteroids.
About the Authors
A. A. Vizel’
Kazan’ State Medical University, Healthcare Ministry of Russia
Russian Federation
Russian Federation
Doctor of Medicine, Professor, Head of Department of Phthisiology and Pulmonology,
ul. Butlerova 49, Kazan', 420012, Tatarstan Republic
I. Yu. Vizel’
Kazan’ State Medical University, Healthcare Ministry of Russia;
Federal State Budgetary Scientific Institution «Central Research Institute of Tuberculosis»
Russian Federation
Russian Federation
Doctor of Medicine, Professor, Russian Academy of Natural Sciences, Associate Professor, Department of Phthisiology and Pulmonology, ul. Butlerova 49, Kazan', 420012, Tatarstan Republic;
Researcher, Yauzskaya alleya 2, Moskow, 107564
G. R. Shakirova
Kazan’ State Medical University, Healthcare Ministry of Russia;
Republican Clinical Hospital of the Ministry of Health of the Republic of Tatarstan
Russian Federation
Russian Federation
Candidate of Medicine, Assistant Lecturer, Department of Phthisiology and Pulmonology, ul. Butlerova 49, Kazan', 420012, Tatarstan Republic;
Pulmonologist, Orenburg tract 138, Kazan, 420064, Tatarstan Republic
References
1. Salah S., Abad S., Brézin A.P., Monnet D. [Sarcoidosis]. J. Fr. Ophtalmol. 2019; 42 (3): 303–321. DOI: 10.1016/j.jfo.2018.06.015 (in French).
2. Bennett D., Bargagli E., Refini R.M., Rottoli P. New concepts in the pathogenesis of sarcoidosis. Expert Rev. Respir. Med. 2019; 13 (10): 981–991. DOI: 10.1080/17476348.2019.1655401.
3. Nunes H., Jeny F., Bouvry D. et al. Indications for treatment of sarcoidosis. Curr. Opin. Pulm. Med. 2019; 25 (5): 505–518. DOI: 10.1097/MCP.0000000000000604.
4. Cremers J.P., Drent M., Bast A. et al. Multinational evidence-based World Association of Sarcoidosis and Other Granulomatous Disorders recommendations for the use of methotrexate in sarcoidosis: integrating systematic literature research and expert opinion of sarcoidologists worldwide. Curr. Opin. Pulm. Med. 2013; 19 (5): 545–561. DOI: 10.1097/MCP.0b013e3283642a7a.
5. Ministerstvo zdravookhraneniya Rossiyskoy Federatsii. Rossiyskoe respiratornoe obshchestvo. [Sarcoidosis: Clinical guidelines]. Available at: www.spulmo.ru›download/2019_КЛИН…САРКОИДОЗ_финал.pdf (in Russian).
6. Isshiki T., Yamaguchi T., Yamada Y. et al. Usefulness of lowdose methotrexate monotherapy for treating sarcoidosis. Intern. Med. 2013; 52 (24): 2727–2732. DOI: 10.2169/internalmedicine.52.0976.
7. Vorselaars A.D., Wuyts W.A., Vorselaars V.M. et al. Methotrexate vs azathioprine in second-line therapy of sarcoidosis. Chest. 2013; 144 (3): 805–812. DOI: 10.1378/chest.12-1728.
8. Goljan-Geremek A., Bednarek M., Franczuk M. et al. Methotrexate as a single agent for treating pulmonary sarcoidosis: a single centre real-life prospective study. Pneumonol. Alergol. Pol. 2014; 82 (6): 518–533. DOI: 10.5603/PiAP.2014.0069.
9. Gavrisyuk V.K., Merenkova E.A., Gumenyuk G.L. et al. [Effectiveness and safety of methotrexate monotherapy in patients with pulmonary sarcoidosis]. Meditsinskie novosti Gruzii = Georgian Medical News. 2018; (283): 34–38 (in Russian).
10. Wang W., Zhou H., Liu L. Side effects of methotrexate therapy for rheumatoid arthritis: A systematic review. Eur. J. Med. Chem. 2018; 158: 502–516. DOI: 10.1016/j.ejmech.2018.09.027.
Review
For citations:
Vizel’ A.A., Vizel’ I.Yu., Shakirova G.R. Evaluation of the efficacy and safety of methotrexate in progressive sarcoidosis: a retrospective observational study. PULMONOLOGIYA. 2020;30(2):213-218. (In Russ.) https://doi.org/10.18093/0869-0189-2020-30-2-213-218
Views:
1934
Email this article 